What is the primary action of sacubitril/valsartan combination therapy in heart failure?

The primary action of sacubitril/valsartan combination therapy in heart failure is vasodilation and natriuresis. This combination works synergistically to improve outcomes in patients with heart failure. Sacubitril is a neprilysin inhibitor, which increases the levels of natriuretic peptides and other vasoactive substances that promote vasodilation, reduce blood pressure, and enhance renal sodium excretion (natriuresis). Valsartan is an angiotensin receptor blocker (ARB) that further aids in vasodilation and reduces the harmful effects of angiotensin II, such as vasoconstriction and sodium retention.

Together, these mechanisms lead to an overall decrease in cardiac workload and fluid overload, which are critical issues in managing heart failure. By promoting vasodilation and natriuresis, this therapy helps alleviate symptoms associated with heart failure and contributes to improved functional capacity and quality of life for patients.